Melanotan I (Afamelanotide): MC1R-Selective Melanocortin, Photoprotection Research

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is Melanotan I?

Melanotan I (MT-I), also known by its pharmaceutical name afamelanotide and the brand name Scenesse, is a synthetic linear analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It is a 13-amino-acid peptide with the sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. The peptide was originally developed at the University of Arizona in the 1980s as part of a research program investigating melanocortin receptor pharmacology and the potential for inducing melanogenesis without UV radiation exposure.

Alpha-MSH is a naturally occurring tridecapeptide produced by the pituitary gland and certain skin cells that plays a central role in regulating pigmentation in mammals. However, native alpha-MSH has an extremely short half-life in circulation, measured in minutes, which limits its utility as a research tool and as a potential therapeutic agent. Melanotan I was designed to address this limitation. By substituting norleucine (Nle) for methionine at position 4 and D-phenylalanine (D-Phe) for L-phenylalanine at position 7, researchers created a peptide with significantly greater enzymatic stability and a longer duration of action than its endogenous counterpart.

What distinguishes Melanotan I within the melanocortin peptide family is its selectivity for the melanocortin 1 receptor (MC1R). This selectivity is a critical pharmacological property that differentiates it from the structurally related but functionally distinct Melanotan II, and it has shaped the direction of Melanotan I research across multiple decades of investigation.

Mechanism of Action: MC1R and Eumelanin Production

Melanotan I exerts its primary observed effects through selective activation of the melanocortin 1 receptor (MC1R), a G protein-coupled receptor expressed predominantly on the surface of melanocytes — the specialized cells responsible for melanin production in the skin. Understanding this mechanism requires a brief overview of the melanogenesis pathway.

The MC1R Signaling Cascade

When Melanotan I binds to MC1R on the melanocyte surface, it activates adenylyl cyclase through a stimulatory G protein (Gs), leading to increased intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP activates protein kinase A (PKA), which in turn phosphorylates the cAMP response element-binding protein (CREB). Phosphorylated CREB translocates to the nucleus and upregulates expression of microphthalmia-associated transcription factor (MITF), the master regulator of melanocyte differentiation and melanin synthesis.

MITF drives the expression of key melanogenic enzymes — tyrosinase, tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2/DCT) — which catalyze the biochemical conversion of tyrosine to melanin pigment within specialized organelles called melanosomes. Critically, this MC1R-driven pathway favors the production of eumelanin, the brown-black pigment that provides superior photoprotection, over pheomelanin, the red-yellow pigment associated with greater UV susceptibility.

Eumelanin vs. Pheomelanin

The distinction between eumelanin and pheomelanin is central to understanding Melanotan I’s research significance. Eumelanin absorbs UV radiation across a broad spectrum and dissipates the energy as heat, providing effective photoprotection. Pheomelanin, by contrast, is not only less effective at UV absorption but can actively generate reactive oxygen species (ROS) when exposed to UV radiation, potentially contributing to oxidative DNA damage. By shifting the eumelanin-to-pheomelanin ratio in favor of eumelanin, MC1R activation represents a mechanistic pathway of interest in photoprotection research.

Beyond Melanocytes: MC1R on Other Cell Types

While melanocytes are the primary cells of interest in Melanotan I research, MC1R is also expressed on keratinocytes, fibroblasts, endothelial cells, and various immune cell populations, including macrophages, monocytes, and neutrophils. Research has demonstrated that MC1R activation on immune cells is associated with anti-inflammatory signaling, including reduced production of pro-inflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6. This broader expression pattern has expanded the research profile of Melanotan I beyond pigmentation into areas of inflammation and immune modulation.

Melanotan I vs. Melanotan II: Key Distinctions

Melanotan I and Melanotan II are frequently discussed together, but they are pharmacologically distinct compounds with different receptor selectivity profiles, structures, and observed effects in research. Clarifying these differences is essential for researchers working with melanocortin peptides.

Property	Melanotan I (MT-I)	Melanotan II (MT-II)
Structure	Linear 13-amino-acid peptide	Cyclic 7-amino-acid peptide
Receptor selectivity	Selective for MC1R	Non-selective (MC1R, MC3R, MC4R, MC5R)
Primary observed effect	Eumelanin production (pigmentation)	Pigmentation + sexual arousal (via MC4R)
MC4R activation	Minimal	Significant — drives sexual and appetite effects
Regulatory status	FDA/EMA approved as Scenesse for EPP	Not approved for any indication
Pharmaceutical name	Afamelanotide	No pharmaceutical designation

The MC1R selectivity of Melanotan I is its defining pharmacological advantage in research contexts where pigmentation is the target outcome. Melanotan II’s activation of MC4R — a receptor expressed in the hypothalamus and involved in sexual arousal, appetite regulation, and energy homeostasis — produces a broader range of effects that are not always desirable in research protocols focused specifically on melanogenesis. PT-141 (bremelanotide), another melanocortin peptide, was in fact derived from Melanotan II specifically to target MC4R-mediated sexual function, illustrating how receptor selectivity within this peptide family determines research and therapeutic direction.

Approved Therapeutic Use: Erythropoietic Protoporphyria (EPP)

Melanotan I, as afamelanotide (brand name Scenesse), represents one of the few melanocortin peptides to have achieved regulatory approval for a therapeutic indication. Its approval pathway and the condition it addresses provide important context for understanding both its pharmacological profile and the state of clinical evidence.

What Is EPP?

Erythropoietic protoporphyria is a rare genetic disorder caused by deficiency of the enzyme ferrochelatase, which leads to accumulation of protoporphyrin IX in red blood cells, plasma, and skin. When individuals with EPP are exposed to visible light (particularly wavelengths around 400-410 nm), protoporphyrin IX absorbs the light energy and generates reactive oxygen species, causing severe phototoxic reactions — intense burning pain, erythema, and edema — that can occur within minutes of light exposure. Unlike sunburn, which is caused by UV radiation, EPP photosensitivity is triggered by visible light, making conventional sunscreens largely ineffective.

EPP affects an estimated 1 in 75,000 to 1 in 200,000 individuals, and patients often experience profound quality-of-life impairment due to light avoidance behaviors that limit outdoor activity, employment, and social participation.

Regulatory Approvals

Afamelanotide received European Medicines Agency (EMA) approval in 2014 for the prevention of phototoxicity in adult patients with EPP. The FDA granted approval in 2019 for the same indication, following a series of clinical trials that demonstrated increased duration of pain-free time in sunlight for treated patients compared to placebo. The approved formulation is a subcutaneous biodegradable implant that releases afamelanotide over approximately 60 days.

Clinical Trial Evidence

The approval of Scenesse was supported by multiple Phase II and Phase III clinical trials conducted across European and American sites. The pivotal Phase III trial (ClinicalTrials.gov: NCT01605136) was a randomized, double-blind, placebo-controlled study that enrolled 94 EPP patients across 17 centers. Results demonstrated that afamelanotide-treated patients experienced significantly more time outdoors in direct sunlight without pain compared to placebo-treated patients. Additional trials examined duration of effect, implant pharmacokinetics, and long-term safety over multiple treatment cycles.

The clinical trial program for afamelanotide in EPP represents the most extensive body of controlled human data for any melanocortin peptide analog, providing important safety and pharmacokinetic information that extends beyond the EPP indication itself.

Research Areas Beyond EPP

While the EPP approval represents the only validated therapeutic application of Melanotan I to date, the peptide’s MC1R-mediated mechanism of action has prompted investigation across several additional research domains.

Photoprotection and UV Damage Prevention

The observation that Melanotan I increases eumelanin content in skin, independent of UV exposure, has driven research interest in its potential as a photoprotective agent in broader populations. Preclinical and early clinical studies have documented measurable increases in skin melanin density following afamelanotide administration, even in fair-skinned individuals with low baseline melanin levels. This UV-independent melanogenesis distinguishes Melanotan I from conventional tanning, which requires UV-induced DNA damage as the initiating stimulus for melanin production.

Research has explored whether pharmacologically induced eumelanin could provide a baseline level of photoprotection that supplements behavioral sun protection measures. Studies have measured melanin optical density, minimal erythema dose (MED), and UV-induced DNA damage markers (such as cyclobutane pyrimidine dimers) in afamelanotide-treated versus control subjects.

Vitiligo

Vitiligo is an autoimmune condition characterized by the destruction of melanocytes, resulting in depigmented patches of skin. Research has investigated whether Melanotan I, by stimulating remaining melanocytes and potentially promoting melanocyte proliferation and migration through MC1R activation, could enhance repigmentation outcomes when combined with phototherapy. Phase II clinical trials have examined afamelanotide as an adjunct to narrowband UVB (NB-UVB) phototherapy in vitiligo patients, with published results reporting accelerated repigmentation in combination-treated groups compared to NB-UVB alone. These studies are notable for suggesting a synergistic interaction between MC1R activation and phototherapy-driven melanocyte stimulation.

Polymorphous Light Eruption (PLE)

Polymorphous light eruption is the most common idiopathic photodermatosis, affecting up to 10-20% of the population in temperate climates. It manifests as an itchy, papular or vesicular rash following sun exposure, typically in spring or early summer. PLE is thought to involve an abnormal immune response to UV-induced neoantigens in the skin. Research has investigated whether afamelanotide-induced eumelanin could reduce UV penetration into the skin sufficiently to attenuate the immunological trigger for PLE. Clinical studies have documented reduced PLE severity scores in afamelanotide-treated subjects, though this remains an investigational application.

Melanoma Prevention Research

The relationship between melanin type and melanoma risk is well established in epidemiological and molecular research. Individuals with MC1R loss-of-function variants — who produce predominantly pheomelanin rather than eumelanin — have significantly elevated melanoma risk. This association has prompted research into whether pharmacological MC1R activation, by shifting pigment production toward eumelanin, could theoretically reduce UV-induced mutagenesis in melanocytes.

This research area requires careful framing. Melanoma prevention is a long-term outcome that cannot be assessed in short-duration clinical trials. Research in this domain has focused on surrogate markers, including UV-induced DNA damage quantification, DNA repair capacity in melanocytes, and the role of eumelanin in scavenging reactive oxygen species. Animal studies using UV-susceptible mouse models have provided preclinical evidence, but extrapolation to human melanoma prevention remains speculative and requires extensive longitudinal investigation.

Anti-Inflammatory and Immunomodulatory Research

The expression of MC1R on immune cells has led to investigation of Melanotan I’s effects beyond pigmentation. Preclinical studies have documented that MC1R agonism reduces inflammatory signaling in macrophages, attenuates neutrophil recruitment, and modulates the NF-kB signaling pathway. While this research is in early stages and primarily involves in vitro and animal models, it represents an expanding area of melanocortin biology that could inform future investigations with MC1R-selective peptides like Melanotan I.

Handling and Reconstitution

Melanotan I is typically supplied as a lyophilized (freeze-dried) powder for research use. Proper handling is essential for maintaining peptide integrity and ensuring reproducible experimental results.

Storage

Lyophilized Melanotan I should be stored at -20°C or below in a desiccated environment, protected from light. Under these conditions, the peptide remains stable for extended periods. Once reconstituted, the solution should be stored at 2-8°C (refrigerated) and used within a reasonable timeframe to minimize degradation.

Reconstitution

For research applications, Melanotan I is reconstituted with bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative). The bacteriostatic agent inhibits microbial growth and allows for multiple withdrawals from the same vial without contamination. When reconstituting, the solvent should be introduced gently along the wall of the vial, and the peptide should be allowed to dissolve without vigorous shaking or vortexing, which can cause aggregation and denaturation of the peptide.

Peptide Stability Considerations

As a linear peptide, Melanotan I is susceptible to enzymatic degradation and oxidation. Methionine residues are particularly vulnerable to oxidation, though the substitution of norleucine at position 4 in the Melanotan I sequence was specifically designed to mitigate this vulnerability. Researchers should minimize repeated freeze-thaw cycles of reconstituted solutions and avoid exposure to strong light or elevated temperatures during experimental protocols.

Related Melanocortin Peptides

Melanotan I belongs to a broader family of melanocortin peptides that interact with the five melanocortin receptor subtypes (MC1R through MC5R). Understanding the relationships between these peptides provides context for Melanotan I’s position within the melanocortin research landscape.

• Melanotan II — A cyclic, non-selective melanocortin agonist that activates MC1R, MC3R, MC4R, and MC5R. Its broader receptor activity produces pigmentation effects similar to Melanotan I but also drives sexual arousal and appetite suppression via MC4R. See the Melanotan II research guide for detailed coverage.
• PT-141 (Bremelanotide) — Derived from Melanotan II, PT-141 is an MC4R agonist that was developed specifically for sexual function research. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. See the PT-141 research guide for further detail.
• KPV — A C-terminal tripeptide fragment of alpha-MSH (Lys-Pro-Val) that has been investigated for anti-inflammatory properties. KPV research has focused on NF-kB inhibition and mucosal inflammation models, representing a distinct but related branch of melanocortin peptide investigation.

Regulatory Status Overview

Melanotan I occupies a unique regulatory position among research peptides due to the approved pharmaceutical product derived from it.

Approved Pharmaceutical (Afamelanotide / Scenesse)

As Scenesse, afamelanotide is an EMA-approved (2014) and FDA-approved (2019) prescription medication for the prevention of phototoxicity in adult EPP patients. It is manufactured as a controlled-release subcutaneous implant and is available only through restricted distribution programs due to the rarity of the target condition.

Research Peptide

Melanotan I is separately available as a research-grade peptide from chemical suppliers for legitimate scientific investigation. The research-grade product is sold as lyophilized powder, distinct from the pharmaceutical implant formulation. It is labeled for research use only and is not intended for human consumption. Researchers should be aware that the availability of an approved pharmaceutical formulation does not extend regulatory approval to research-grade peptide products, which remain governed by research chemical regulations in their respective jurisdictions.

WADA Status

Melanotan I is not specifically listed on the World Anti-Doping Agency (WADA) Prohibited List as a named substance, though it may fall under the S0 category (Non-Approved Substances) depending on its form and context of use. Researchers involved in sports science should verify the current WADA classification before incorporating melanocortin peptides into athletic research protocols.

Frequently Asked Questions

What is the difference between Melanotan I and afamelanotide?

Melanotan I and afamelanotide are the same peptide. Afamelanotide is the International Nonproprietary Name (INN) adopted for pharmaceutical and clinical use, while Melanotan I is the original research designation. The brand name Scenesse refers to the specific pharmaceutical formulation — a controlled-release subcutaneous implant — approved for EPP.

Why is Melanotan I considered more selective than Melanotan II?

Melanotan I is a linear 13-amino-acid analog that retains the natural alpha-MSH preference for MC1R. Melanotan II is a truncated, cyclized 7-amino-acid peptide whose constrained structure increases binding affinity across multiple melanocortin receptor subtypes (MC1R through MC5R). This non-selectivity means Melanotan II activates MC4R (involved in sexual function and appetite) and MC3R (involved in energy homeostasis) in addition to MC1R. Melanotan I’s linear structure and longer sequence preserve the native selectivity profile of alpha-MSH for MC1R.

What is the amino acid sequence of Melanotan I?

The full sequence is Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. Two key modifications from native alpha-MSH are the substitution of norleucine (Nle) at position 4, which improves oxidative stability, and D-phenylalanine (D-Phe) at position 7, which enhances enzymatic resistance and receptor binding potency.

What is erythropoietic protoporphyria?

EPP is a rare genetic disorder caused by ferrochelatase deficiency, leading to accumulation of protoporphyrin IX in the blood and skin. Protoporphyrin IX absorbs visible light and generates reactive oxygen species, causing severe phototoxic reactions — burning pain, redness, and swelling — within minutes of light exposure. Conventional sunscreens are largely ineffective because the trigger is visible light, not UV radiation. Afamelanotide (Scenesse) is approved to reduce phototoxicity in adult EPP patients by increasing eumelanin, which absorbs light energy and provides photoprotection.

How does Melanotan I differ from natural tanning?

Natural tanning is a reactive process: UV radiation damages DNA in keratinocytes, which triggers p53 activation and release of alpha-MSH precursors, ultimately stimulating melanocytes to produce melanin. This process requires UV-induced DNA damage as its initiating event. Melanotan I bypasses this pathway entirely by directly activating MC1R on melanocytes, stimulating eumelanin production without the prerequisite DNA damage. This UV-independent mechanism is the basis of its investigation as a photoprotective research compound.

What reconstitution method is recommended for research use?

Melanotan I should be reconstituted with bacteriostatic water, introduced slowly along the vial wall to avoid peptide aggregation. The reconstituted solution should be stored at 2-8°C, protected from light, and used within a reasonable period. Repeated freeze-thaw cycles should be avoided, as they can degrade linear peptides and reduce experimental reproducibility.

---

Summary of Key Research References

Study / Source	Year	Type	Focus
Scenesse Phase III (NCT01605136)	2015	RCT (Phase III)	Afamelanotide for EPP — pain-free time in sunlight
EMA Scenesse Approval	2014	Regulatory	European approval for EPP prevention
FDA Scenesse Approval	2019	Regulatory	U.S. approval for EPP phototoxicity prevention
Hadley & Dorr (University of Arizona)	1980s–2000s	Original research	Development of alpha-MSH analogs (MT-I, MT-II)
Langan et al.	2012	Clinical trial	Afamelanotide + NB-UVB in vitiligo repigmentation
Grimes et al.	2013	Phase II	Afamelanotide combined with NB-UVB for vitiligo
Schölermann et al.	Various	Clinical studies	PLE severity and afamelanotide intervention
Abdel-Malek et al.	2006–2020	Mechanistic research	MC1R signaling, eumelanin, DNA repair in melanocytes
Wolf Horrell et al.	2016	Review	MC1R structure, function, and role in pigmentation

---

Research Disclaimer

For laboratory and research use only. Not for human consumption.

This article is intended solely as a summary of published scientific research on Melanotan I (afamelanotide). It does not constitute medical advice, treatment recommendations, or an endorsement of Melanotan I for any therapeutic purpose beyond its approved indication. While afamelanotide is FDA/EMA-approved as Scenesse for erythropoietic protoporphyria, research-grade Melanotan I is a distinct product sold strictly for laboratory and research purposes. The research discussed herein spans preclinical and clinical investigations, and conclusions from individual studies should be interpreted within the context of their specific methodologies and limitations. Researchers should consult relevant institutional review boards and regulatory guidelines before designing studies involving this compound.

NorthPeptide supplies research-grade peptides for legitimate scientific investigation. All products are sold strictly for laboratory and research purposes. https://northpeptide.com/products/melanotan-i